FF, your #47087 is a terrific overview of Bavi's Anti-Cancer moa, especially bringing to light why Bavi appears to have such potential against Refractory/Chemo-Resistant tumors, the very target of the new ‘registrational’ Ph.2 Bavi+Doce/2nd-Line-NSCLC trial put together by RGarnick, S.King & Team. If you don't mind, I'm going to add your post to the end of my "Peregrine’s Ambitious Bavi Goal: Accelerated Approval after PhaseII” post from yesterday, so it’ll be there when I update it when significant news events/updates occur down the road. Much thanks.
Market Data 
Markets 
AI
